Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Apimeds Pharmaceuticals US, Inc. ( (APUS) ) has provided an update.
On December 30, 2025, stockholders of Apimeds Pharmaceuticals US, Inc. removed board member Erik Emerson by written consent through a majority vote of the outstanding common stock entitled to elect directors, acting in accordance with the company’s governing documents and applicable law. Following this governance change, the company’s board of directors continues to comprise Elona Kogan, Jakap Koo, Carol O’Donnell, and Dr. Bennett Weintraub, PhD, signaling a reshaped but functioning leadership structure for the pharmaceutical company’s ongoing oversight.
More about Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. operates in the pharmaceutical industry, though this release does not specify its primary products, services, or market focus beyond its status as a Delaware-incorporated company with a shareholder base entitled to vote on director elections.
Average Trading Volume: 90,639
Technical Sentiment Signal: Strong Sell
Current Market Cap: $20.62M
Learn more about APUS stock on TipRanks’ Stock Analysis page.